| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | -0.023 | 0.9 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.024 | 0.9 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | 0.0083 | 0.9 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | -0.0055 | 0.9 |